About this trial

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS), patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.

Eligibility criteria

Qualifiers

Age ≥ 12 years old,Any gender;

The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine);

patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;

Sign the informed consent form.

Disqualifiers

According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;

Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;

According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);

Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;

Trial design

Treatments tested in this trial

  • Medicine Overuse Headache/New Daily Persistent Headache
  • Episodic Migraine and Chronic Migraine
  • Patients with other types of primary headache
  • Yangxue Qingnao Granules (Pills)
  • Erenumab
  • Eptinezumab

Treatment groups

10,000 Participants
are divided into 4 treatment groups

Locations

20
Beijing Chaoyang Hospital BeijingBeijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University100070, BeijingBeijing Municipality, China
Chongqing People's Hospital ChongqingChongqing Municipality, China
Fujian Provincial Hospital FuzhouFujian, China

Sponsors and collaborators

Beijing Tiantan Hospital

Lead sponsor